Multiorgan Pathology in Chronic Obstructive Pulmonary Disease (COPD)
COPD: Transition of Systemic Inflammation Into Multiorgan Pathology (Study 3). (De Effecten Van Ontsteking op Skeletspieren Bij COPD)
There is increasing evidence in the literature that COPD should not be considered as a localised pulmonary disorder but as a systemic disease involving pathology in several extra pulmonary tissues. Well characterized systemic features are a chronic low grade systemic inflammation, altered body composition and a skeletal muscle fibre type shift. There are indications that an absolute or relative increase of fat mass puts COPD patients at increased risk for cardiovascular pathology while muscle atrophy is associated with a high prevalence of osteoporosis and with impaired physical function. The origin of systemic inflammation is poorly understood. Both endogenous and exogenous risk factors contribute to systemic inflammation and extra-pulmonary manifestations of COPD.
Overall objective of study 3:
To compare the pattern and severity of the systemic inflammatory profile in relation to skeletal muscle weakness and cardiovascular risk profile in COPD patients with mild to moderate disease compared to non-susceptible smokers.
Specific objectives:
- To study the relative contribution of pulmonary and extra pulmonary factors on exercise capacity, skeletal muscle function and health status
- To relate diet, physical activity and cardiovascular risk factors to body composition, skeletal muscle function and exercise capacity status
- To study the influence of the emphysema phenotype on extra pulmonary pathology in COPD
- To study muscle fibre type size and composition and to relate muscle oxidative phenotype with insulin sensitivity, inflammation (local and systemic) and molecular signatures of oxidative energy and protein metabolism.
Study design:
Cross-sectional study. Healthy smoking subjects and COPD patients will undergo extensive clinical, metabolic and inflammatory assessment at the university clinics in Groningen, Maastricht and CIRO Horn.
Study population:
Totally 60 subjects will be included
- 30 healthy subjects who after 20 pack years smoking have no signs of COPD (age 40-75 years)
- 30 COPD patients with GOLD stage II (age 40-75 years)
調査の概要
状態
条件
詳細な説明
Primary study parameters/outcome of the study:
- Smoking history and behaviour, diet and physical activity level assessed by questionnaire
- Extensive lung function and CT scanning of the lung, ECG
- Candidate genes for muscle dysfunction and CVD risk
- Body composition (BIA, waist-hip ratio, DEXA-scan)
- Systemic inflammation
- Advanced Glycosylated Endproduct (AGE)
- Glucose tolerance test
- Risk factors of metabolic syndrome
- 6 minute walking distance
- Handgrip strength
- Skeletal muscle function by isokinetic dynamometry
- Physical activity level and pattern by accelerometry
- Muscle oxidative phenotype, fibre cross-sectional area and molecular signatures obtained in vastus lateralis muscle biopsies before and after incremental cycle ergometry
Nature and extent of the burden and risks associated with participation, benefit and group relatedness (if applicable):
- Totally 22 hours will be spend in the hospital during 3 visits
- CT-scanning of the lung is associated with a radiation burden of 0.8-1.6 mSv (dependent of body weight)
- 50 ml peripheral blood (v. cubiti)
- Muscle biopsy may be associated with temporary pain and haematoma
- Drawing of arterial blood from the radial artery rarely leads to bleeding and transitory nerve damage (numb feeling in wrist/hand area).
研究の種類
入学 (予想される)
連絡先と場所
研究場所
-
-
Limburg
-
Maastricht、Limburg、オランダ、6200 MD
- Maastricht University Medical Center, Dept. of Respiratory Medicine
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Totally 60 subjects will be included
- 30 healthy subjects with 20 pack years smoking who have no signs of COPD (age 40-75 years)
- 30 COPD patients with GOLD stage II (age 40-75 years)
説明
Inclusion Criteria:
- Age 40-75 years
- Age, pack years, FEV1/FVC and FEV1% predicted must fit in one of 2 groups of table 4.3
- Physically and mentally able to undergo the total study protocol
- Written informed consent
Exclusion Criteria:
- Participation in another study
- Alpha-1-antitrypsin deficiency
- Selected grade 1-3 co-morbidity listed in the ACE-27
- Active pulmonary infection like tuberculosis, pneumonia, flue, tracheobronchitis
- Active extra-pulmonary infection like hepatitis A-C, cystitis, gastroenteritis etc.
- Pulmonary diseases like sarcoidosis, IPF, silicosis, hypersensitivity pneumonitis, asthma
- Life threatening diseases like carcinoma, AIDS (including HIV+), acute leukemia etc.
- Medication that may affect the results of the study: NSAID's, immunosuppressive agents like prednisolon, methotrexate, azathioprine, sintrom tablets, askal
- Antibiotic or prednisolon use in the past 2 months
研究計画
研究はどのように設計されていますか？
デザインの詳細
コホートと介入
グループ/コホート |
|---|
|
1
• 30 healthy subjects with 20 pack years smoking who have no signs of COPD (age 40-75 years)
|
|
2
• 30 COPD patients with GOLD stage II (age 40-75 years)
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
|---|
|
徒歩6分
|
|
体組成
|
|
握力
|
|
Smoking history and behaviour, diet and physical activity level assessed by questionnaire
|
|
Extensive lung function and CT scanning of the lung, ECG
|
|
Candidate genes for muscle dysfunction and CVD risk
|
|
Systemic inflammation
|
|
Advanced Glycosylated Endproduct (AGE)
|
|
Glucose Tolerance Test
|
|
Risk factors of metabolic syndrome
|
|
Skeletal muscle function by isokinetic dynamometry
|
|
Physical activity level and pattern by accelerometry
|
|
Muscle oxidative phenotype, fibre cross-sectional area and molecular signatures obtained in vastus lateralis muscle biopsies before and after incremental cycle ergometry
|
協力者と研究者
スポンサー
協力者
捜査官
- 主任研究者：Emiel Wouters, Prof. dr. MD、Maastricht University Medical Center, Dept. of Respiratory Medicine
研究記録日
主要日程の研究
研究開始
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 23475
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。